REG-4basebio Plc: New lease and expansion of manufacturing capacity

4BasebioAnnouncement

03/04/2023 12:15

03 April 2023

4basebio PLC

("4basebio", the "Company" or the “Group”)

Signing of new lease and expansion of manufacturing capacity

4basebio PLC (AIM: 4BB), the specialist life sciences group focused on
exploiting intellectual property in the field of cell and gene therapies and
DNA vaccines, announces a further expansion of its UK facilities.

In light of the continued expansion of its commercial capabilities, 4BB is
relocating its manufacturing and quality assurance teams to new premises
adjacent to its existing clean room facilities.  Consequently, it has entered
into a lease (“Lease”) to rent the premises which provide dedicated
laboratory, warehousing and office space for those teams.

The additional property brings the overall footprint in the UK to 21,000
square feet and reflects the growth in the UK team to more than 60 staff today
and provides room for further expansion.

The Lease is for 13 years with an annual cost of approximately £9 per square
foot and has been prepared on the basis of standard commercial terms. The
property’s ownership includes persons related to Heikki Lanckriet, the
Company’s CEO and CSO.  

Related Party Transaction

As a result of the property, over which the Company has entered into the
Lease, being part owned by persons related to a director, entering into the
Lease by the Company constitutes a related party transaction
(“Transaction”) pursuant to the AIM Rules for Companies.  With the
exception of Dr Lanckriet, the directors of the Company, having consulted with
the Company's Nominated Adviser, Cairn Financial Advisers LLP, consider the
terms of the Transaction to be fair and reasonable insofar as the Company’s
shareholders are concerned.

Dr Heikki Lanckriet, CEO and CSO for 4basebio, commented: “The addition of
the new premises locates the manufacturing and quality assurance teams
alongside the company’s clean rooms; moreover it will allow the company to
continue expanding its commercial teams at its main facility, thereby
accelerating the company’s capacity to onboard new clients moving
forward.”

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the
European Union (Withdrawal) Act 2018).

For further enquiries, please contact:

 4basebio PLC                                       +44 (0)12 2396 7943 
 Heikki Lanckriet, CEO                                                  
                                                                        
 Cairn Financial Advisers LLP (Nominated Adviser)   +44 (0)20 7213 0880 
 Jo Turner / Sandy Jamieson                                             
                                                                        
 finnCap Ltd (Broker)                                                   
 Geoff Nash/Richard Chambers/Charlotte Sutcliffe    +44 (0)20 7220 0500 
                                                                        
                                                                        

Notes to Editors

4basebio (AIM: 4BB) is a specialist life sciences group focused on therapeutic
DNA for cell and gene therapies and DNA vaccines and providing solutions for
effective and safe delivery of these DNA based products to patients. It is the
intention of the Company to become a market leader in the manufacture and
supply of high purity, synthetic DNA for research, therapeutic and
pharmacological use and develop non-viral vectors for the efficient delivery
of payloads. The immediate objectives of 4bb are to validate and scale its DNA
synthesis and advance its collaborations to facilitate the functional
validation of its DNA based products and cell and gene delivery solutions.

Forward-looking statements

This announcement may contain certain statements about the future outlook for
the 4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved